Prof. Haifa Kathrin Al-Ali: Exclusive Insights from EHA 2025

Published on June 20, 2025

The Global MPN Scientific Foundation is proud to share an exclusive message from Prof. Haifa Kathrin Al-Ali, hematologist and oncologist at the University Hospital of Halle (Germany), recorded during the European Hematology Association (EHA) Congress 2025 in Milan, Italy.

As a Key Opinion Leader (KOL) in the field of Myeloproliferative Neoplasms (MPNs), Prof. Al-Ali brings clarity and credibility to the latest updates shared at EHA—one of the most important hematology events of the year.

In her message, she highlights:

  • The growing relevance of combination therapies

  • New data on anemia management and JAK inhibitors

  • Breakthroughs in treatments for CALR mutations

  • The value of including the patient voice in research and pharma

EHA is more than a conference—it’s where future treatments begin to take shape. And hearing it from trusted experts makes all the difference. 🎥 Watch the full video:

https://vimeo.com/1094960422/3fe5438196?share=copy 

Stay informed at www.mpnworld.org

 

Other news

Insights from EHA 2025 – Peter Löffelhardt shares a message of hope

June 19, 2025
📍 Milan, June 12–15, 2025Peter Löffelhardt, Founder and CEO of the Global MPN Scientific Foundation, attended the European Hematology Association (EHA) Congress 2025 to connect with researchers, pharmaceutical companies, and patient advocates from around the world.In his words:“There’s real momentum in the MPN field. While no new treatments are expected in the next two years, promising therapies

Would you like to participate in a clinical trial on myeloproliferative neoplasms (MPN)?

June 23, 2025
Myeloproliferative neoplasms (MPNs) are rare cancers of the blood that result from genetic changes in the cells that make blood in the bone marrow. These changes cause too many red blood cells, white blood cells, or platelets to be produced, which can lead to various problems and symptoms.    MPNs were first identified in 1951, but the genetic causes were only evident once the JAK2 V617F mutation